Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia

Archives of General Psychiatry

Volumn 66, Issue 1, 2009, Pages 81-87

  Small, Gary W ^a   Siddarth, Prabha ^a   Burggren, Alison C ^a   Kepe, Vladimir ^a   Ercoli, Linda M ^a   Miller, Karen J ^a   Lavretsky, Helen ^a   Thompson, Paul M ^a   Cole, Greg M ^a   Huang, S C ^a   Phelps, Michael E ^a   Bookheimer, Susan Y ^a   Barrio, Jorge R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 [6 [(2 [F 18]FLUOROETHYL)(METHYL)AMINO] 2 NAPHTHYL]ETHYLIDENE]MALONONITRILE; APOLIPOPROTEIN E4; CONTRAST MEDIUM; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; CINGULATE GYRUS; CLINICAL STUDY; COGNITION; COGNITIVE DEFECT; DEMENTIA; EDUCATIONAL STATUS; FAMILY HISTORY; FEMALE; FRONTAL CORTEX; GENETIC RISK; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; TEMPORAL CORTEX;

AGED; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; CEREBRAL CORTEX; COGNITION DISORDERS; EDUCATIONAL STATUS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; NEUROFIBRILLARY TANGLES; NEUROPSYCHOLOGICAL TESTS; NITRILES; POSITRON-EMISSION TOMOGRAPHY; RISK FACTORS; SENILE PLAQUES; TAU PROTEINS;

EID: 58149482094     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2008.516     Document Type: Article

References (63)

1. Small GW, Bookheimer SY, Thompson PM, Cole GM, Huang S-C, Kepe V, Barrio JR. Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol. 2008;7(2):161-172.
2. Larrabee GJ, Crook TH. Estimated prevalence of age-associated memory im-pairment derived from standardized tests of memory function. Int Psychogeriatr. 1994;6(1):95-104.
3. Jorm AF, Christensen H, Korten AE, Henderson AS, Jacomb PA, Mackinnon A. Do cognitive complaints either predict future cognitive decline or reflect past cognitive decline? a longitudinal study of an elderly community sample. Psychol Med. 1997;27(1):91-98.
4. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004; 256(3):183-194.
5. Fischer P, Jungwirth S, Zehetmayer S, Weissgram S, Hoenigschnabl S, Gelpi E, Krampla W, Tragl KH. Conversion from subtypes of mild cognitive impairment to Alzheimer dementia. Neurology. 2007;68(4):288-291.
6. Lopez OL, Jagust WJ, DeKosky ST, Becker JT, Fitzpatrick A, Dulberg C, Breitner J, Lyketsos C, Jones B, Kawas C, Carlson M, Kuller LH. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study. Arch Neurol. 2003;60(10):1385-1389.
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
8. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944.
9. Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, Burke JR, Hurd MD, Potter GG, Rodgers WL, Steffens DC, Willis RJ, Wallace RB. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29(1-2):125-132.
10. Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, Hebert LE, Hennekens CH, Taylor JO. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA. 1989; 262(18):2551-2556.
11. Hebert LE, Scherr PA, Beckett LA, Albert MS, Pilgrim DM, Chown MJ, Funkenstein HH, Evans DA. Age-specific incidence of Alzheimer's disease in a community population. JAMA. 1995;273(17):1354-1359.
12. Jorm AF, Jolley D. The incidence of dementia: a meta-analysis. Neurology. 1998; 51(3):728-733.
13. Small GW. What we need to know about age related memory loss. BMJ. 2002;324 (7352):1502-1505.
14. Corder EH, Saunders AM, Strittmatter WJ, Schmechel D, Gaskell P, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993; 261(5123):921-923.
15. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, Rimmler JB, Locke PA, Conneally PM, Schmader KE, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7(2):180-183.
16. van Duijn CM, Clayton D, Chandra V, Fratiglioni L, Graves AB, Heyman A, Jorm AF, Kokmen E, Kondo K, Mortimer JA. Familial aggregation of Alzheimer's disease and related disorders: a collaborative re-analysis of case-control studies: EURODEM Risk Factors Research Group. Int J Epidemiol. 1991;20(suppl 2): S13-S20.
17. Huang W, Qiu C, von Strauss E, Winblad B, Fratiglioni L. APOE genotype, family history of dementia, and Alzheimer disease risk: a 6-year follow-up study. Arch Neurol. 2004;61(12):1930-1934.
18. Stern Y, Gurland B, Tatemichi TK, Tang MX, Wilder D, Mayeux R. Influence of education and occupation on the incidence of Alzheimer's disease. JAMA. 1994; 271(13):1004-1010.
19. Wilson RS, Mendes De Leon CF, Barnes LL, Schneider JA, Bienias JL, Evans DA, Bennett DA. Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA. 2002;287(6):742-748.
20. Ngandu T, von Strauss E, Helkala EL, Winblad B, Nissinen A, Tuomilehto J, Soin-inen H, Kivipelto M. Education and dementia: what lies behind the association? Neurology. 2007;69(14):1442-1450.
21. Del Ser T, Hachinski V, Merskey H, Munoz DG. An autopsy-verified study of the effect of education on degenerative dementia. Brain. 1999;122(pt12):2309-2319.
22. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259.
23. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol. 1999;45(3):358-368.
24. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-319.
25. 11C]SB-13 PET. Am J Geriatr Psychiatry. 2004;12(6):584-595.
26. Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, Read S, Satyamurthy N, Petric A, Huang SC, Barrio JR. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer's disease. Am J Geriatr Psychiatry. 2002;10(1):24-35.
27. 18F]fluoroethyl)(methyl)amino]- 2-naphthyl}ethylidene) malononitrile. Neuroscience. 2003;117(3):723-730.
28. Small GW, Kepe V, Ercoli L, Siddarth P, Miller K, Bookheimer SY, LavretskyH, Burggren AC, Cole G, Vinters HV, Thompson PM, Huang S-C, Satyamurthy N, Phelps ME, Barrio JR. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006;355(25):2652-2663.
29. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-198.
30. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23:56-62.
31. Lezak M, Howieson D, Loring D. Neuropsychological Assessment. 4th ed. New York, NY: University Press; 2004.
32. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256(3):240-246.
33. de Jager CA, Budge MM. Stability and predictability of the classification of mild cognitive impairment as assessed by episodic memory test performance over time. Neurocase. 2005;11(1):72-79.
34. Busse A, Hensel A, Gühne U, Angermeyer MC, Riedel-Heller SG. Mild cognitive impairment: long-term course of four clinical subtypes. Neurology. 2006;67 (12):2176-2218.
35. Gilewski MJ, Zelinski EM. Questionnaire assessment of memory complaints. In: Poon LW, ed. Handbook for Clinical Memory Assessment of Older Adults. Washington, DC: American Psychological Association; 1986:93-107.
36. Logan J, Fowler J, Volkow N, Wang G, Ding Y, Alexoff D. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16(5):834-840.
37. Talairach J, Tournoux P. Coplanar Stereotaxic Atlas of the Human Brain: Three-Dimensional Proportional System: an Approach to Cerebral Imaging. New York, NY: Thieme; 1988.
38. Petersen RC, Parisi JE, Dickson DW, Johnson KA, Knopman DS, Boeve BF, Ji-cha GA, Ivnik RJ, Smith GE, Tangalos EG, Braak H, Kokmen E. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol. 2006;63(5):665-672.
39. Ohm TG, Scharnagl H, März W, Bohl J. Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer's disease-related lesions. Acta Neuropathol. 1999;98(3):273-280.
40. Warzok RW, Kessler C, Apel G, Schwarz A, Egensperger R, Schreiber D, Herbst EW, Wolf E, Walther R, Walker LC. Apolipoprotein E4 promotes incipient Alzheimer pathology in the elderly. Alzheimer Dis Assoc Disord. 1998;12(1):33-39.
41. Tiraboschi P, Hansen LA, Masliah E, Alford M, Thal LJ, Corey-Bloom J. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology. 2004;62(11):1977-1983.
42. Kleiman T, Zdanys K, Black B, Rightmer T, Grey M, Garman K, Macavoy M, Gel-ernter J, van Dyck C. Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis. Dement Geriatr Cogn Disord. 2006;22(1):73-82.
43. Hoyt BD, Massman PJ, Schatschneider C, Cooke N, Doody RS. Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease. Arch Neurol. 2005;62(3):454-459.
44. Murphy GM Jr, Taylor J, Kraemer HC, Yesavage J, Tinklenberg JR. No association between apolipoprotein E epsilon 4 allele and rate of decline in Alzheimer's disease. Am J Psychiatry. 1997;154(5):603-608.
45. Dal Forno G, Rasmusson DX, Brandt J, Carson KA, Brookmeyer R, Troncoso J, Kawas CH. Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease. Arch Neurol. 1996;53(4):345-350.
46. Gomez-Isla T, West HL, Rebeck GW, Harr SD, Growdon JH, Locascio JJ, Perls TT, Lipsitz LA, Hyman BT. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann Neurol. 1996;39(1):62-70.
47. Tyas SL, Salazar JC, Snowdon DA, Desrosiers MF, Riley KP, Mendiondo MS, Kryscio RJ. Transitions to mild cognitive impairments, dementia, and death: findings from the Nun Study. Am J Epidemiol. 2007;165(11):1231-1238.
48. Amieva H, Letenneur L, Dartigues JF, Rouch-Leroyer I, Sourgen C, D'Alchée-Birée F, Dib M, Barberger-Gateau P, Orgogozo JM, Fabrigoule C. Annual rate and predictors of conversion to dementia in subjects presenting mild cognitive impairment criteria defined according to a population-based study. Dement Geri-atrCogn Disord. 2004;18(1):87-93.
49. Kryscio RJ, Schmitt FA, Salazar JC, Mendiondo MS, Markesbery WR. Risk factors for transitions from normal to mild cognitive impairment and dementia. Neurology. 2006;66(6):828-832.
50. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18(4):351-357.
51. Ghebremedhin E, Schultz C, Braak E, Braak H. High frequency of apolipoprotein E epsilon4 allele in young individuals with very mild Alzheimer's disease-related neurofibrillary changes. Exp Neurol. 1998;153(1):152-155.
52. Ghebremedhin E, Schultz C,Thal DR, Rüb U, Ohm TG, Braak E, Braak H. Gender and age modify the association between APOE and AD-related neuropathology. Neurology. 2001;56(12):1696-1701.
53. Troncoso JC, Zonderman AB, Resnick SM, Crain B, Pletnikova O, O'Brien RJ. Effect of infarcts on dementia in the Baltimore longitudinal study of aging. Ann Neurol. 2008;64(2):168-176.
54. Van Den Heuvel C, Thornton E, Vink R. Traumatic brain injury and Alzheimer's disease: a review. Prog Brain Res. 2007;161:303-316.
55. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'brien J, Pasquier F, Robert P, RossorM, Salloway S, Stern Y, Visser PJ, Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734-746.
56. Prince M, Cullen M, Mann A. Risk factors for Alzheimer's disease and dementia: a case-control study based on the MRC elderly hypertension trial. Neurology. 1994;44(1):97-104.
57. Persson G, Skoog I. Subclinical dementia: relevance of cognitive symptoms and signs. J Geriatr Psychiatry Neurol. 1992;5(3):172-178.
58. La Rue A, O'Hara R, Matsuyama SS, Jarvik LF. Cognitive changes in young-old adults: effect of family history of dementia. J Clin Exp Neuropsychol. 1995; 17(1):65-70.
59. Fratiglioni L, Ahlbom A, Viitanen M, Winblad B. Risk factors for late-onset Alzheimer's disease: a population-based, case-control study. Ann Neurol. 1993; 33(3):258-266.
60. Tyas SL, Manfreda J, Strain LA, Montgomery PR. Risk factors for Alzheimer's disease: a population-based, longitudinal study in Manitoba, Canada. Int J Epidemiol. 2001;30(3):590-597.
61. Lindsay J, Laurin D, Verreault R, Hébert R, Helliwell B, Hill GB, McDowell I. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol. 2002;156(5):445-453.
62. Silverman JM, Smith CJ, Marin DB, Mohs RC, Propper CB. Familial patterns of risk in very late-onset Alzheimer disease. Arch Gen Psychiatry. 2003;60(2): 190-197.
63. Aston JA, Cunningham VJ, Asselin MC, Hammers A, Evans AC, Gunn RN. Positron emission tomography partial volume correction: estimation and algorithms. J Cereb Blood Flow Metab. 2002;22(8):1019-1034.